The Indian Pharma Market (IPM) created a conducive growth environment in 2025 for March at 9.3% YoY, which shows a remarkable recovery from the months gone by. Key growth drivers included Cipla...
According to recent information collected from the U.S. Food and Drug Administration (FDA), major leading pharmaceutical firms in India are recalling...
Researchers in the US have utilized advanced CRISPR interference technology to discover a new collection of genes that enhance the likelihood of developing Parkinson's disease...
With the increasing scrutiny on drug safety and efficacy, understanding impurities is more important than ever and ever evolving guidelines are not aiding the efforts. To address those lacunas, Eminence has come up with 3rd Annual Pharma Impurity Con
With patient safety becoming more critical than ever in today's evolving healthcare landscape, the demand for robust drug safety practices continues to surge. After several successful editions in India and Dubai, Eminence Group returns with 4th Editi
A promising therapeutic option has been proposed at the Jawaharlal Nehru Centre for Advanced Scientific Research for treating...
Cipla made significant progress after obtaining USFDA permission for marketing its generic cancer drug. The USFDA granted Cipla authorization to introduce their paclitaxel protein-bound particles for injectable suspension (albumin-bound) under the br
Researchers believe that they have unearthed a fresh genetic cause of neurodevelopmental disorders that have never before...
The Drug Administration Department of Karnataka has withdrawn defective medications totaling Rs 24.3 lakh from the market as part of a campaign against subpar pharmaceuticals.
Novartis is launching its latest investment initiative shortly after President Donald Trump introduced sweeping new tariffs on...